We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Renal Denervation in Patients With Refractory Hypertension

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 7, 2007
Last Update Posted: November 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Medtronic Vascular
To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.

Condition Intervention Phase
Hypertension Device: Ardian Symplicity™ Catheter Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Renal Denervation in Patients With Refractory Hypertension

Further study details as provided by Medtronic Vascular:

Primary Outcome Measures:
  • To provide confirmation that renal denervation is safe and feasible. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Evidence of renal denervation; indication of physiologic response; assessment of device performance. [ Time Frame: 3 years ]

Enrollment: 73
Study Start Date: June 2007
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Denervation
Renal denervation using the Symplicty Catheter
Device: Ardian Symplicity™ Catheter
Renal denervation using the Symplicity Catheter


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >= 18 years of age.
  • a systolic blood pressure of 160 mmHg or greater.
  • receiving and adhering to full doses of an appropriate antihypertensive drug regimen for a minimum of two weeks prior to screening.
  • agrees to have the study procedure(s) performed and additional procedures and evaluations, including repeat phlebotomy, imaging, urine analyses, and clinical examination.
  • competent and willing to provide written, informed consent to participate in this clinical study.

Exclusion Criteria:

  • renal arterial abnormalities
  • end stage renal disease requiring dialysis or renal transplant
  • serum Cr > 3, or calculated GFR < 45 ml/min
  • has experienced MI, unstable angina pectoris, or CVA with 6 months
  • others
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483808

Australia, Victoria
St. Vincent's Hospital
Fitzroy, Victoria, Australia, 3065
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
John Paul II Hospital
Krakow, Poland
Sponsors and Collaborators
Medtronic Vascular
Principal Investigator: Henry Krum, MBBS,PhD The Alfred Hospital and Monash University, Melbourne, VIC, Australia
Principal Investigator: Robert Whitbourn, MBBS, FRACP St. Vincent's Hospital, Fitzroy, VIC, Australia
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Medtronic Vascular
ClinicalTrials.gov Identifier: NCT00483808     History of Changes
Other Study ID Numbers: TP-015 & TP-038
First Submitted: June 5, 2007
First Posted: June 7, 2007
Last Update Posted: November 5, 2013
Last Verified: November 2013

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases